Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Burlington, VT
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Burlington, VT
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
A 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-stage Renal Disease (ESRD) on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Bosutinib In Subjects With Renal Impairment
An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Bosutinib In Subjects With Renal Impairment
An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Omaha, NE
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Omaha, NE
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
A Study of Fostamatinib in Subjects With Impaired Kidney Function
An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of Fostamatinib in Subjects With Impaired Kidney Function
An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients
Status: Archived
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
Monitoring for Donor-Specific Hyporesponsiveness Following Renal and Pancreatic Allotransplantation
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
Monitoring for Donor-Specific Hyporesponsiveness Following Renal and Pancreatic Allotransplantation
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Click here to add this to my saved trials
Kidney Disease Biomarkers
Kidney Disease Biomarkers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Kidney Disease Biomarkers
Kidney Disease Biomarkers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Intravenous Voriconazole in Patients With Renal Compromise
Intravenous Voriconazole in Patients With Renal Compromise
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Intravenous Voriconazole in Patients With Renal Compromise
Intravenous Voriconazole in Patients With Renal Compromise
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
City of Hope Antelope Valley
mi
from
Lancaster, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
City of Hope Antelope Valley
mi
from
Lancaster, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Hospital - Martinez
mi
from
Martinez, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Hospital - Martinez
mi
from
Martinez, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
City of Hope South Pasadena
mi
from
South Pasadena, CA
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials